文献速递肺外科

美国CoC标准5.8全国执行率评估及其对淋巴结升期与手术并发症的影响

National Assessment of Adherence to Commission on Cancer Standard 5.8 and its Impact on Nodal Upstaging Rates and Operative Morbidity.
PubMed 文献 · Ann Thorac Surg · 2026-09-10

基于STS胸外科数据库2021年7月至2024年12月52,497例临床I-IIIA期非小细胞肺癌切除患者,仅66.4%达到3+1淋巴结站评估标准,达标中心比例从19.3%升至43.5%。

要点

  • 全国仅66.4%肺癌切除达到CoC标准5.8的3+1淋巴结评估要求。
  • 达标中心比例从19.3%升至43.5%,但2024年底多数中心仍未达80%基准。
  • 达标与淋巴结升期增加相关,未增加总体并发症或死亡。

核心结论

  • CoC标准5.8执行率随时间上升,但2024年底多数中心仍未达到80%的依从性基准。
  • 达标与病理淋巴结升期率升高相关,且未伴随总体并发症或死亡率的增加。

研究设计与样本

  • 回顾性队列研究,数据来自胸外科医师学会普胸外科数据库。
  • 纳入2021年7月1日至2024年12月31日因临床I-IIIA期非小细胞肺癌行切除的患者,共52,497例。
  • 比较达标(3+1)与未达标患者的淋巴结升期率及主要并发症或死亡,并采用多因素分析评估达标相关因素。

主要发现

  • 52,497例中34,871例(66.4%)达到3+1标准,且该比例随时间增加。
  • 达标中心(依从性≥80%)比例从19.3%上升至43.5%。
  • 与达标相关的因素包括亚洲种族(aOR 1.15;p<0.001)、当前吸烟(aOR 1.22;p<0.001)或既往吸烟(aOR 1.11;p<0.001)、肺段切除(aOR 2.67;p<0.001)或肺叶切除(aOR 3.75;p<0.001)。
  • 达标与未达标组间总体并发症或死亡率无差异。

关键数值与推荐

  • CoC标准5.8要求任一机构80%的治愈性非小细胞肺癌切除标本评估≥3个N2和≥1个N1淋巴结站(3+1)。
  • 达标定义为满足3+1淋巴结站评估。
  • 依从性≥80%的中心比例从19.3%增至43.5%。

临床怎么用

  • 胸外科医生应确保肺癌切除时至少评估3个N2站和1个N1站以满足CoC标准5.8。
  • 提高淋巴结评估依从性可增加病理淋巴结升期检出,且不增加总体并发症或死亡风险。
  • 机构应监测3+1达标率以持续改进肺癌手术质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Commission on Cancer (CoC) Standard 5.8 requires that 80% of curative resections for non-small cell lung cancer (NSLC) at any single institution have ≥3 N2 and ≥1 N1 lymph node stations assessed (3+1). We sought to assess national adherence rates and the impact on nodal upstaging and operative morbidity. METHODS: Patients who underwent resection for clinical stage I-IIIA non-small cell lung cancer between 7/1/2021-12/31/2024 were identified from the Society of Thoracic Surgeons General Thoracic Surgical Database. We evaluated the percentage of resections that met the 3+1 standard. Rates of nodal upstaging and major morbidity or mortality were compared between those meeting the standard versus those who did not. Multivariable analysis was used to assess factors associated with meeting the standard. RESULTS: 34,871 of 52,497 (66.4%) patients had resections that met the 3+1 standard and this increased over time. Centers meeting ≥80% adherence increased from 19.3% to 43.5%. Factors associated with meeting the standard included Asian race (aOR 1.15; p<0.001), currently (1.22; p<0.001), or formerly smoking (aOR 1.11; p<0.001), and segmentectomy (aOR 2.67; p<0.001) or lobectomy (aOR 3.75; p<0.001). Pathologic nodal upstaging was higher in cases that met the 3+1 standard (aOR 1.19, [CI 1.12-1.27]). There were no differences in overall morbidity or mortality. CONCLUSIONS: The percentage of resection that met Standard 5.8 increased over time; however, most centers still did not meet the 80% adherence benchmark by the end of 2024. Adherence was associated with an increase in pathologic upstaging, without a corresponding increase in major morbidity or mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Krantz SB, Seder CW, Lizarraga IM, et al. National Assessment of Adherence to Commission on Cancer Standard 5.8 and its Impact on Nodal Upstaging Rates and Operative Morbidity. Ann Thorac Surg. 2026. PMID: 42722266. doi:10.1016/j.athoracsur.2026.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。